ギランバレー症候群診断市場- 世界の産業規模、シェア、動向、機会、予測、検査別、最終用途別、地域別、競合別、2020～2030年

ギランバレー症候群診断の世界市場は、2024年に1億5,095万米ドルと評価され、予測期間中のCAGRは5.12%で、2030年には1億7,342万米ドルに達すると予測されています。

ギランバレー症候群（GBS）は、身体の免疫系が誤って末梢神経系を攻撃し、筋力低下、しびれ、重症の場合は麻痺を引き起こす、稀な重篤な神経疾患です。早期かつ正確な診断は、効果的な管理および治療のために非常に重要ですが、この疾患の多様性や他の神経疾患との重複症状が、その特定を困難にしています。

GBSの診断には、まず詳細な臨床検査と病歴聴取が必要です。医師は、典型的には下肢から始まり上半身に向かう筋力低下の発現と進行を評価します。反射神経はしばしば低下したり消失したりしますが、これはGBSの顕著な特徴です。また、しびれや痛みなどの感覚障害、血圧変動や心拍異常などの自律神経障害を訴えることもあります。GBSは多くの場合、先行する感染症が引き金となって発症するため、医師は呼吸器感染症や胃腸障害などの最近の病気について質問します。

神経伝導検査（NCS）と筋電図検査（EMG）は、GBSを確認するために不可欠な診断手段です。NCSは末梢神経の電気信号の速さと強さを測定します。GBSでは、神経の脱髄や軸索の損傷により、これらの信号が遅くなったり遮断されたりします。神経刺激に対する筋肉の反応を評価するEMGは、GBSを他の神経筋疾患と区別するのに役立ちます。これらの検査結果から、急性炎症性脱髄性多発ニューロパチー（AIDP）や急性運動軸索性ニューロパチー（AMAN）など、GBSのサブタイプに関する貴重な知見が得られます。

腰椎穿刺（脊髄穿刺）は、脳と脊髄を取り囲む脳脊髄液（CSF）を分析するためにしばしば行われます。GBSの場合、髄液分析では通常、アルブミン細胞学的解離として知られる所見である白血球の有意な増加を伴わない蛋白レベルの上昇が認められます。しかし、この特徴的な徴候は疾患の初期には認められないことがあり、臨床的疑いが高い場合には繰り返し検査が必要となります。

市場促進要因

ギランバレー症候群の発生率の上昇

主な市場課題

限られた認知度と誤診

主要市場動向

診断技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のギランバレー症候群診断市場に与える影響

第5章 世界のギランバレー症候群診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 検査別（腰椎穿刺、筋電図検査、その他）
  • 最終用途別（病院・診療所、診断研究所、その他）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米のギランバレー症候群診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のギランバレー症候群診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のギランバレー症候群診断市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のギランバレー症候群診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのギランバレー症候群診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（ある場合）
• テスト起動（ある場合）
• 最近の動向

第13章 世界のギランバレー症候群診断市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Cadwell Industries, Inc
• Natus Medical Incorporated
• Nihon Kohden Corporation
• Medtronic plc
• Bionen s.r.l.
• Deymed Diagnostic s.r.o.
• Neurosoft Ivanovo, Russia
• Alpine Biomedicals Pvt Ltd.
• EMS Handels Gesellschaft m.b.H.
• Rochester Electro-Medical, Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Guillain-Barre Syndrome Diagnostics Market was valued at USD 150.95 Million in 2024 and is expected to reach USD 173.42 Million by 2030 with a CAGR of 5.12% during the forecast period. Guillain-Barre Syndrome (GBS) is a rare but serious neurological disorder in which the body's immune system mistakenly attacks the peripheral nervous system, leading to muscle weakness, numbness, and in severe cases, paralysis. Early and accurate diagnosis is critical for effective management and treatment, but the condition's variability and overlapping symptoms with other neurological disorders make its identification challenging.

The first step in diagnosing GBS involves a detailed clinical examination and patient history. Physicians assess the onset and progression of muscle weakness, typically starting in the lower limbs and ascending toward the upper body. Reflexes are often diminished or absent, a hallmark characteristic of GBS. Patients may also report sensory disturbances, such as tingling or pain, and autonomic dysfunction, including blood pressure fluctuations and abnormal heart rhythms. Since GBS is often triggered by a preceding infection, doctors inquire about recent illnesses such as respiratory infections or gastrointestinal disturbances.

Nerve conduction studies (NCS) and electromyography (EMG) are essential diagnostic tools for confirming GBS. NCS measures the speed and strength of electrical signals in the peripheral nerves. In GBS, these signals are slowed or blocked due to nerve demyelination or axonal damage. EMG, which assesses muscle response to nerve stimulation, can help distinguish GBS from other neuromuscular conditions. The results of these tests provide valuable insights into the subtype of GBS, such as acute inflammatory demyelinating polyneuropathy (AIDP) or acute motor axonal neuropathy (AMAN).

A lumbar puncture (spinal tap) is often performed to analyze cerebrospinal fluid (CSF), which surrounds the brain and spinal cord. In GBS, CSF analysis typically reveals elevated protein levels without a significant increase in white blood cells, a finding known as albuminocytological dissociation. However, this hallmark feature may not be present in the early stages of the disease, requiring repeated testing if clinical suspicion remains high.

Key Market Drivers

Rising Incidence of Guillain-Barre Syndrome

Guillain-Barre Syndrome (GBS) is an autoimmune disorder in which the body's immune system mistakenly attacks the peripheral nervous system, leading to muscle weakness, paralysis, and, in severe cases, respiratory failure. The global rise in the incidence of GBS has become a significant concern for healthcare providers, prompting increased demand for accurate and timely diagnostic solutions. The growing number of GBS cases worldwide, fueled by viral infections, vaccinations, and other autoimmune triggers, is a key driver of the expanding Guillain-Barre Syndrome diagnostics market. According to the National Organization for Rare Disorders (NORD), Guillain-Barre Syndrome (GBS) impacts approximately one to two individuals per 100,000 people annually.

One of the major factors contributing to the rising incidence of GBS is the increased prevalence of viral infections such as Zika virus, cytomegalovirus, and Epstein-Barr virus, which have been linked to the onset of the syndrome. Additionally, seasonal influenza and COVID-19 infections have also been associated with a higher risk of developing GBS. The correlation between these infections and GBS has intensified the need for early and precise diagnostic tools, including cerebrospinal fluid (CSF) analysis, electromyography (EMG), and nerve conduction studies (NCS), which are essential for confirming GBS and differentiating it from other neurological disorders.

Advancements in diagnostic technologies are further propelling market growth. Innovations in biomarker detection, molecular diagnostics, and imaging techniques have enhanced the ability to identify GBS in its early stages, leading to improved patient outcomes. Additionally, artificial intelligence (AI)-driven diagnostic solutions are being developed to enhance the accuracy and efficiency of GBS detection. These technological advancements are helping to meet the growing demand for rapid and reliable diagnostic procedures, further expanding the market.

Key Market Challenges

Limited Awareness and Misdiagnosis

One of the primary challenges in the GBS diagnostics market is the lack of awareness among healthcare providers and the general population. Guillain-Barre Syndrome presents with symptoms similar to other neurological disorders, such as multiple sclerosis and myasthenia gravis, leading to frequent misdiagnosis or delayed identification. This delay in diagnosis can significantly impact patient outcomes, as early intervention is critical in managing the condition effectively.

Key Market Trends

Technological Advancements in Diagnostics

One of the key trends shaping the GBS diagnostics market is the advancement in diagnostic technologies. Modern electrophysiological tests, such as NCS and EMG, are becoming more precise and efficient, aiding in the differentiation of GBS subtypes. Additionally, biomarker research has gained traction, with efforts focused on identifying specific autoantibodies and inflammatory markers that could improve the accuracy of GBS diagnosis. The integration of artificial intelligence (AI) and machine learning in medical imaging and electrophysiology has the potential to enhance diagnostic efficiency, reducing the time needed for clinical decision-making.

Key Market Players

• Cadwell Industries, Inc
• Natus Medical Incorporated
• Nihon Kohden Corporation
• Medtronic plc
• Bionen s.r.l.
• Deymed Diagnostic s.r.o.
• Neurosoft Ivanovo, Russia
• Alpine Biomedicals Pvt Ltd.
• EMS Handels Gesellschaft m.b.H.
• Rochester Electro-Medical, Inc.

Report Scope

In this report, the Global Guillain-Barre Syndrome Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Guillain-Barre Syndrome Diagnostics Market, By Test:

• Lumbar Puncture
• Electromyography
• Others

Guillain-Barre Syndrome Diagnostics Market, By End use:

• Hospitals And Clinics
• Diagnostic Laboratories
• Others

Guillain-Barre Syndrome Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Guillain-Barre Syndrome Diagnostics Market.

Available Customizations:

Global Guillain-Barre Syndrome Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Guillain-Barre Syndrome Diagnostics Market

5. Global Guillain-Barre Syndrome Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test (Lumbar Puncture, Electromyography, Others)
  • 5.2.2. By End Use (Hospitals And Clinics, Diagnostic Laboratories, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Guillain-Barre Syndrome Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Guillain-Barre Syndrome Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test
      • 6.3.1.2.2. By End Use
  • 6.3.2. Mexico Guillain-Barre Syndrome Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test
      • 6.3.2.2.2. By End Use
  • 6.3.3. Canada Guillain-Barre Syndrome Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test
      • 6.3.3.2.2. By End Use

7. Europe Guillain-Barre Syndrome Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Guillain-Barre Syndrome Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test
      • 7.3.1.2.2. By End Use
  • 7.3.2. Germany Guillain-Barre Syndrome Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Guillain-Barre Syndrome Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Guillain-Barre Syndrome Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Guillain-Barre Syndrome Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test
      • 7.3.5.2.2. By End Use

8. Asia Pacific Guillain-Barre Syndrome Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Guillain-Barre Syndrome Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Guillain-Barre Syndrome Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test
      • 8.3.2.2.2. By End Use
  • 8.3.3. South Korea Guillain-Barre Syndrome Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test
      • 8.3.3.2.2. By End Use
  • 8.3.4. Japan Guillain-Barre Syndrome Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Guillain-Barre Syndrome Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test
      • 8.3.5.2.2. By End Use

9. South America Guillain-Barre Syndrome Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Guillain-Barre Syndrome Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Guillain-Barre Syndrome Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Guillain-Barre Syndrome Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Guillain-Barre Syndrome Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Guillain-Barre Syndrome Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Guillain-Barre Syndrome Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Guillain-Barre Syndrome Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Test Launches (If Any)
• 12.3. Recent Developments

13. Global Guillain-Barre Syndrome Diagnostics Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Cadwell Industries, Inc
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Natus Medical Incorporated
• 15.3. Nihon Kohden Corporation
• 15.4. Medtronic plc
• 15.5. Bionen s.r.l.
• 15.6. Deymed Diagnostic s.r.o.
• 15.7. Neurosoft Ivanovo, Russia
• 15.8. Alpine Biomedicals Pvt Ltd.
• 15.9. EMS Handels Gesellschaft m.b.H.
• 15.10. Rochester Electro-Medical, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer